Caenorhabditis elegans as a model for exploring the efficacy of synthesized organoruthenium complexes for aging and Alzheimer's disease a neurodegenerative disorder: A systematic approach

Abstract The current article deals with the preparation and characterisation of new organoruthenium(II) complexes, namely [RuCp(Dea-Sal-tsc)(PPh 3 )] ( 1 ), [RuCp(Dea-Sal-mtsc)(PPh 3 )] ( 2 ), [RuCp(Dea-Sal-etsc)(PPh 3 )] ( 3 ) and [RuCp(Dea-Sal-ptsc)(PPh 3 )] ( 4 ). The new ruthenium(II) complexes were characterized by various analytical, spectral techniques. The structure of the ligand [H 2 -Dea-Sal-tsc] and the complex [RuCp(Dea-Sal-tsc)(PPh 3 )] ( 1 ) were confirmed by X-ray crystallography. The complexes ( 1–4 ) were used to study the toxicity, stress resistance, aging and neuro-protective effects by taking Caenorhabditis elegans as model. In vitro free radical scavenging activity was performed by DPPH free radical scavenging assay, the complexes ( 1–4 ) exhibited highest scavenging activity than standard Vitamin C (IC 50  = 5.28 ± 0.10). The lifespan has increased over 22.4% in mev-1 mutant worms treated with complex 4 . The complex 4 triggered the DAF-16 nuclear localization, increases sod-3 expression and reduced amyloid (A β ) protein induced paralysis were observed. In the present study we confirmed that oxidative stress resistance of N2 and lifespan extension of mev-1 mutant which showed the potential ROS scavenging activity of complex 4 . The results also confirmed the effective anti-aging potential of ruthenium complex 4 which may be developed as a therapeutic drug for the prevention of aging and age related neurodegenerative diseases. Further studies are required to find out the exact action of complex 4 on higher model.